PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Morphoproteomics Identifies the EZH2 and SIRT1 Pathways as Potential Blocks to Differentiation in Yolk Sac Tumor of the Ovary and Provides Therapeutic Options: a Case Study.

Abstract Yolk sac tumor of the ovary is a rare but highly malignant and aggressive germ cell tumor. The objective of this case study of an ovarian yolk sac tumor was to identify putative pathways that are known to pose a block in differentiation, both in early embryogenesis and in tumorigenesis, that might be amenable to low toxicity therapies designed to promote differentiation to a more benign state and prevent recurrent disease in such tumors. The enhancer of Zeste homolog 2 (EZH2), a histone methyl transferase, and silent mating type information regulation 2 homolog 1 (SIRT1), a NAD+ histone deacetylase, are two such pathways.
PMID
Related Publications

Krukenberg tumor with yolk sac tumor differentiation.

Transcription factor GATA-6 is expressed in malignant endoderm of pediatric yolk sac tumors and in teratomas.

Gonadoblastoma and hepatoid and endometrioid-like yolk sac tumor: an update.

Prognosis of hepatoid yolk sac tumor in women: what's up, Doc?

Morphoproteomics Identifies SIRT1 and EZH2 Pathways as Commonalities in B-cell Acute Lymphoblastic Leukemia: Pathogenetic Implications and Opportunities for Therapeutic Intervention.

Authors

Mayor MeshTerms

Cell Differentiation

Signal Transduction

Keywords

EZH2

Morphoproteomics

SIRT1

yolk sac tumor

Journal Title annals of clinical and laboratory science
Publication Year Start




PMID- 28249923
OWN - NLM
STAT- MEDLINE
DA  - 20170302
DCOM- 20170313
LR  - 20170313
IS  - 1550-8080 (Electronic)
IS  - 0091-7370 (Linking)
VI  - 47
IP  - 1
DP  - 2017 Jan
TI  - Morphoproteomics Identifies the EZH2 and SIRT1 Pathways as Potential Blocks to
      Differentiation in Yolk Sac Tumor of the Ovary and Provides Therapeutic Options: 
      a Case Study.
PG  - 88-91
AB  - Yolk sac tumor of the ovary is a rare but highly malignant and aggressive germ
      cell tumor. The objective of this case study of an ovarian yolk sac tumor was to 
      identify putative pathways that are known to pose a block in differentiation,
      both in early embryogenesis and in tumorigenesis, that might be amenable to low
      toxicity therapies designed to promote differentiation to a more benign state and
      prevent recurrent disease in such tumors. The enhancer of Zeste homolog 2 (EZH2),
      a histone methyl transferase, and silent mating type information regulation 2
      homolog 1 (SIRT1), a NAD+ histone deacetylase, are two such pathways.
CI  - (c) 2017 by the Association of Clinical Scientists, Inc.
FAU - Kojima, Yumi A
AU  - Kojima YA
AD  - Department of Pathology and Laboratory Medicine, UT Health-McGovern Medical
      School, Houston, TX, USA Yumi.a.kojima@uth.tmc.edu.
FAU - Assylbekova, Binara
AU  - Assylbekova B
AD  - Department of Pathology and Laboratory Medicine, UT Health-McGovern Medical
      School, Houston, TX, USA.
FAU - Zhao, Bihong
AU  - Zhao B
AD  - Department of Pathology and Laboratory Medicine, UT Health-McGovern Medical
      School, Houston, TX, USA.
FAU - Nugent, Elizabeth
AU  - Nugent E
AD  - Department of Obstetrics and Gynecology UT Health-McGovern Medical School,
      Houston, TX, USA.
FAU - Brown, Robert E
AU  - Brown RE
AD  - Department of Pathology and Laboratory Medicine, UT Health-McGovern Medical
      School, Houston, TX, USA.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Ann Clin Lab Sci
JT  - Annals of clinical and laboratory science
JID - 0410247
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.1.1.43 (Enhancer of Zeste Homolog 2 Protein)
RN  - EC 3.5.1.- (Sirtuin 1)
SB  - IM
MH  - Adult
MH  - Biomarkers, Tumor/metabolism
MH  - *Cell Differentiation
MH  - Endodermal Sinus Tumor/*metabolism/*pathology
MH  - Enhancer of Zeste Homolog 2 Protein/*metabolism
MH  - Female
MH  - Humans
MH  - Ovarian Neoplasms/*metabolism/pathology
MH  - Proteomics/*methods
MH  - *Signal Transduction
MH  - Sirtuin 1/*metabolism
MH  - Tomography, X-Ray Computed
OTO - NOTNLM
OT  - *EZH2
OT  - *Morphoproteomics
OT  - *SIRT1
OT  - *yolk sac tumor
EDAT- 2017/03/03 06:00
MHDA- 2017/03/14 06:00
CRDT- 2017/03/03 06:00
AID - 47/1/88 [pii]
PST - ppublish
SO  - Ann Clin Lab Sci. 2017 Jan;47(1):88-91.

<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
</b:Sources>